AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04758988 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DermLoop Learn
Description: DermLoop Learn is our AI augmented digital online educational system with case training on a library of 10,000+ benign and malignant skin lesion as well as written learning modules for the most common skin lesion diagnosis.
Study NCT06487936 — intervention group
Intervention type: DEVICE
Intervention: TransLoc 3D SI Joint Fusion System
Description: Satisfaction survey will be administered to collect real world evidence on patients that previously received the TransLoc 3D System commercially.
Study NCT05648539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The mini apps named SOUL GYM on the Wechat
Description: Music Therapy can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.
Study NCT04779034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of heart rate variability
Description: Heart rate variation will be evaluated with the Polar RS800CX model heart rate monitor
Study NCT05277532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training (HIIT)
Description: HIIT performed either in the morning or in the afternoon
Study NCT05544760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CatchU Intervention
Description: The CatchU Intervention arm will receive individualized recommendations (adapted from the CDC STEADI program) as outlined on the CatchU physician report sent to the participants physicians. These recommendations in combination with falls intervention referrals and falls counseling tips will be monitored and statistical investigation of the impact of CatchU intervention in preventing future falls will be determined.
Study NCT05498870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block (ACB) Only
Description: Patients will receive an ACB with lidocaine skin wheal
Study NCT05498870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block (ACB) + iPACK Block
Description: Patients will receive an ACB with iPACK block
Study NCT05662722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: percutaneous needle electrolysis
Description: It´s an intervention of physiotherapy. It´s an invasive technique.
Study NCT05662722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dry needling
Description: It´s an intervention of physiotherapy. It´s an invasive technique.
Study NCT05662722 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: It´s an intervention of physiotherapy. It´s an invasive technique simulation.
Study NCT06451458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHO program for DMMC
Description: For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.
Study NCT06451458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.
Study NCT06497985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5mg/kg intravenously (IV) Q3W
Study NCT06497985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruquintinib
Description: 5mg orally QD
Study NCT05860751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling with electrical stimulation
Description: Administered for a total of 2 sessions at a frequency of once per week. The target muscles to be needled will include the gastronemius, soleus, vastus lateralis, rectus femoris, anterior tibialis, posterior tibialis, biceps femoris, and gluteus medius.
Study NCT04650256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Description: CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.
Study NCT06641050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Triage+ Score
Description: The TriAGE+ score is used to evaluate the risk of cerebrovascular disease in patients presenting with dizziness. The score assists in determining the necessity of advanced diagnostic evaluation for stroke, potentially improving diagnostic accuracy and patient outcomes.
Study NCT06639581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 20 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 20-rates per minute
Study NCT06639581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 30 rates per minute
Study NCT06639581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 40 per minute stimulus
Description: crossover randomized mechanical dorsal stimuli -for one minute each- at 40 rates per minute
Study NCT05155085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1(IgG1)monoclonal antibody directed against Siglec-8
Study NCT05155085 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT06640348 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06641206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain
Study NCT06641206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain
Study NCT06641206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline
Study NCT04801173 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Very low calorie ketogenic diet
Description: Dietary intervention with a very low calorie ketogenic diet, using commercial products of the Pronokal PnK® method
Study NCT04801173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie standard diet
Description: Low calorie standard diet with no specified dietary supplement addition
Study NCT04801173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie standard diet
Description: Low calorie standard diet with no specified dietary supplement addition
Study NCT04260854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: Bupivacaine hydrochloride (Hospira, Inc) is an FDA approved, local, injectable indicated for the production of local or regional anesthesia or analgesia for surgery.
Study NCT04260854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline injections.
Study NCT06643078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL231 Solution for Inhalation
Description: HL231 Solution for Inhalation, 3ml:261 μg/141μg, once per day via PARI BOY nebulizer, consisting of a fixed dose combination of indacaterol 261µg and glycopyrronium 141µg, treatment period; 52-weeks fixed dose.
Study NCT06643078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultibro 110μg/50 μg
Description: Ultibro capsule for inhalation once per day via Breezhaler, consisting of a fixed dose combination of indacaterol 110µg and glycopyrronium 50µg, treatment period; 52-weeks fixed dose.
Study NCT06639945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial MR-guided focused ultrasound
Description: MRI-guided transcranial focused ultrasound (MRgFUS) combines magnetic resonance imaging (MRI) with focused ultrasound to target specific areas in the brain non-invasively. MRgFUS allows for treatment without surgical incisions, leading to fewer risks and a quicker recovery. MRI provides real-time imaging that helps precisely locate and treat affected brain regions, such as the thalamus or globus pallidus.The procedure allows for continuous monitoring of the treatment effects, enabling adjustments as needed.
Study NCT06047925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printed crown
Description: Reduction will be performed on the occlusal surface using a flame stone or a wheel stone, to perform occlusal clearance by 1 mm. Reduction will be performed by 1 mm on the mesial, distal, buccal and lingual surfaces of the tooth. Impression for the preparation will be taken using putty and light poly vinyl siloxane material. Temporary crown will be placed above the preparation as temporisation.The impression will be sent to the lab .The preparation will be optically scanned in the lab and the restoration will be digitally designed using computer designing software.The crown will be printed using 3D printer using hybrid resin(micro-filled hybrid material) material.The 3d printed crown is cemented with resin cement.
Study NCT06047925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stanless steel crown
Description: The occlusal surface of the tooth should be reduced by about 1.5 mm, maintaining its occlusal contour or until the tooth is out of occlusion with adequate room to fit a crown.Proximally, tooth reduction will be made through the mesial and distal contact areas, then roundation of line angles to avoid the creation of ledges or steps.The crown selection will be done by trial and error or by measuring the mesiodistal dimension of the tooth space with dividers. It can also be helpful to measure the dimension of the contralateral tooth. A correctly fitting crown should snap or click at try in.
Study NCT06645392 — intervention group
Intervention type: DEVICE
Intervention: visual transparent bladed trocar of
Description: visual transparent bladed trocar of diameter 10 mm and Ternamian bladeless trocar of diameter 10 mm
Study NCT06645392 — intervention group
Intervention type: DEVICE
Intervention: Ternamian bladeless trocar
Description: Ternamian bladeless trocar of diameter 10 mm
Study NCT06643624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vision Training Program
Description: Vision training (experimental) group; vision training program was applied in addition to routine training programs. For 8 weeks, 5 sessions per week for a total of 40 sessions of vision training were applied by a physiotherapist. In the first 2 weeks, each movement was applied for 1 minute for a total of 10 minutes. In the 3rd week, each movement was practiced for 1.5 minutes for a total of 15 minutes. In weeks 4-8, each movement was performed for 2 minutes each for a total of 20 minutes.
Study NCT06643624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Training Program
Description: All athletes performed their routine training for wrestling 6 days a week.
Study NCT06643624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Training Program
Description: All athletes performed their routine training for wrestling 6 days a week.
Study NCT05927298 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Standard of care intervention
Study NCT05743673 — intervention group
Intervention type: DEVICE
Intervention: Shape II
Description: cardiopulmonary exercise testing apparatus
Study NCT05406401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zilovertamab Vedotin
Description: IV infusion
Study NCT05406401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion
Study NCT05406401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion
Study NCT05406401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion
Study NCT05406401 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: IV infusion
Study NCT05406401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: IV or oral administration (per local guidelines)
Study NCT05406401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: IV or oral administration (per local guidelines)
Study NCT06505395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2008 injection
Description: The patients will accept SYHX2008 injection by subcutaneous administration every cycle.
Study NCT06505395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandostatin LAR@
Description: The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.
Study NCT04806399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials and Decision Counseling
Description: Participants in the active comparator arm will receive an introductory letter and lung cancer screening educational materials. A site care coordinator will contact each participant post receiving materials.
Study NCT06635850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosliciguat
Description: Dose level 1, 2, or 3 for inhalation
Study NCT06635850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosliciguat
Description: Dose level 1, 2, or 3 for inhalation
Study NCT06635850 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Powder Inhaler
Description: Dry powder inhaler for mosliciguat or placebo delivery
Study NCT06635850 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dry Powder Inhaler
Description: Dry powder inhaler for mosliciguat or placebo delivery
Study NCT05613881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and Telephone Follow-up
Description: The individuals in this group will be given an education and training booklet by the researcher after the pre-tests are applied in the first face-to-face interview. After the first meeting, the individual will be called every 15 days, 5 times in total for 3 months, and the training will be repeated in line with the individual's needs. After 3 months, the final tests will be applied.
Study NCT06635850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Powder Inhaler
Description: Dry powder inhaler for mosliciguat or placebo delivery
Study NCT06281938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight estimation using 3D camera
Description: Total body weight, ideal body weight and lean body weight estimates will be obtained using a 3D camera system. This weight will be used for calculation of weight-based drug doses and other weight-based interventions.
Study NCT06281938 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care weight estimation
Description: Standard care (unspecified) will be used to determine weight-based dosing and other management.
Study NCT05934942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin®
Description: Ethinylestradiol (EE) and Drospirenone (DRSP)
Study NCT05934942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: BI 1358894
Study NCT04979923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
Study NCT04979923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
Study NCT04979923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
Study NCT05341856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosorbide mononitrate
Description: insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
Study NCT05341856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isosorbide mononitrate
Description: insert vaginal tablet of isosorbide mononitrate in cases of unexplained recurrent pregnancy loss
Study NCT05928182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: El Faro Treatment Intervention
Description: Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\]~Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks.~Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\].
Study NCT05341856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
Study NCT05341856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: insert vaginal tablet of placebo in cases of unexplained recurrent pregnancy loss
Study NCT06080698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Antibiotics
Description: Participants will continue to receive intravenous antibiotics until the completion of the treatment course
Study NCT06080698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antibiotics
Description: Participants will transition to oral antibiotics at the time of randomization and will continue oral antibiotics until the completion of the treatment course
Study NCT06022822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Urolithin A Supplement
Description: Given PO
Study NCT06361550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VENREDI group
Description: Practical seminars aimed at improving the Mediterranean diet, guided by researchers.
Study NCT06635850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for inhalation
Study NCT06361550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education on Mediterranean diet
Study NCT04834336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training device
Description: Inspiratory muscle training will be performed with an inspiratory muscle training device.
Study NCT05154916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Relaxation Program
Description: Virtual Reality Based Relaxation Program
Study NCT06429410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified formula milk powder
Description: Fortified formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, β-hydroxy-β-methylbutyrate, and sodium hyaluronate per day orally for 24 weeks.
Study NCT04834336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
Study NCT04834336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training will be performed with exercise including balance, mobility, functional strength, and endurance.
Study NCT06628960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Su Jok Therapy
Description: Su Jok Therapy
Study NCT06429410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: formula milk powder
Description: Formula milk powder supplemented with whey protein, calcium, vitamin D, colostrum basic protein, and sodium hyaluronate per day orally for 24 weeks.
Study NCT06429410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: regular milk powder
Description: Regular milk powder does not contain and additional supplementation, and the color, flavor, shape, taste, and weight are same with the formula milk powder.
Study NCT05198635 — intervention group
Intervention type: DEVICE
Intervention: local cerebral oxygen saturation
Description: minimum SctO2, SctO2 drop/rise defined by different thresholds, and area under/above the threshold
Study NCT05968937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg baclofen vaginal suppository daily per vagina
Description: 20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy